ASRT
Assertio Holdings, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$23.50
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 102.2M | 118.7M | 125.0M | 152.1M | 156.2M |
| Cost of Revenue | 56.9M | 65.4M | 39.2M | 27.0M | 18.7M |
| Gross Profit | 45.3M | 53.3M | 85.7M | 125.0M | 137.5M |
| Operating Expenses | |||||
| R&D Expense | 1.7M | 1.7M | 3.8M | 2.8M | — |
| SG&A Expense | 66.3M | 68.9M | 77.0M | 69.7M | 48.1M |
| General & Admin Expense | — | — | 75.2M | 65.3M | 44.7M |
| Selling & Marketing Expense | — | — | 1.8M | 4.4M | 3.4M |
| Other Expenses | — | — | 29.4M | 296.0M | 50.0M |
| Total Operating Expenses | 68.0M | 70.5M | 110.2M | 368.6M | 98.1M |
| Cost and Expenses | 124.9M | 135.9M | 149.4M | 395.6M | 116.8M |
| Operating Income (EBIT) | (22.8M) | (17.2M) | (24.5M) | (243.5M) | 39.4M |
| Non-Operating | |||||
| Interest Income | 2.4M | 2.7M | 3.2M | — | — |
| Interest Expense | 3.1M | 3.1M | 3.0M | 3.4M | 8.0M |
| Net Interest Income | (671.0K) | (410.0K) | 182.0K | (3.4M) | (8.0M) |
| Other Non-Op Income/Expense | (12.7M) | (12.7M) | 2.9M | (10.5M) | (8.2M) |
| Non-Operating Income (excl Interest) | 9.6M | 9.6M | (3.8M) | (268.5M) | (17.4M) |
| EBT (Pre-Tax Income) | (35.5M) | (29.9M) | (21.5M) | (254.1M) | 31.2M |
| Income Tax Expense | 235.0K | 435.0K | 52.0K | 77.9M | (78.5M) |
| Bottom Line | |||||
| Net Income | (35.7M) | (30.4M) | (21.6M) | (331.9M) | 109.6M |
| Earnings from Cont. Ops | (35.7M) | (30.4M) | (21.6M) | (331.9M) | 109.6M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (35.7M) | (30.4M) | (21.6M) | (331.9M) | 109.6M |
| Per Share | |||||
| Basic EPS | ($5.54) | ($4.74) | ($3.45) | ($70.05) | $34.95 |
| Diluted EPS | ($5.69) | ($4.74) | ($3.45) | ($70.05) | $30.45 |
| Revenue Per Share | $15.88 | $18.54 | $19.67 | $32.11 | $49.86 |
| Shares | |||||
| Basic Shares Outstanding | 6.4M | 6.4M | 6.4M | 4.7M | 3.1M |
| Diluted Shares Outstanding | 6.4M | 6.4M | 6.4M | 4.7M | 3.6M |
| Profitability Metrics | |||||
| EBITDA | (5.8M) | 3.1M | 5.1M | 53.2M | 90.2M |
| D&A | 26.6M | 30.0M | 25.8M | 28.2M | 33.4M |
| EBIT | (32.4M) | (26.9M) | (20.7M) | 24.9M | 56.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026